NCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT06401824 2025-05-06
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Maastricht University Medical Center
Phase 2 Recruiting
NCT06728865 2024-12-11
Better Brain
Sun Yat-sen University
Phase 2 Recruiting
NCT05807893 2024-11-13
SUPER BRAIN
Sun Yat-sen University
Phase 2/3 Completed
NCT04345146 2023-08-28
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
Sun Yat-sen University
Phase 2 Completed
NCT00312728 2023-01-06
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Phase 2 Completed
NCT02655536 2018-07-10
BRILLIANT
National Taiwan University Hospital
Phase 2 Unknown
NCT01891708 2013-07-03
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Huazhong University of Science and Technology
Unknown